Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.1M
5M shares
52-week range
$0.51 – $586.00
0% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
380.52%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — |
| R&D | $283.0K | $111.0K | $90.0K | $3.4M | $5.1M |
| Operating income | −$3.2M | −$3.2M | −$5.3M | −$15.4M | −$36.8M |
| EBITDA | −$3.7M | −$4.9M | $3.1M | −$15.8M | −$36.5M |
| Net income | −$3.7M | −$4.9M | −$535.0K | −$17.8M | −$39.2M |
| Net margin | — | — | — | — | — |
| EPS (diluted) | -75.00 | -20136.00 | -26760.00 | -61593.00 | -1177.90 |
Annual figures · source: Financial Modeling Prep
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
www.cdtequity.comNo one on the platform currently holds CDT.
No tracked institution reports a position in CDT as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-03-27 | 1-for-25reverse |
| 2025-10-13 | 1-for-8reverse |
| 2025-05-20 | 1-for-15reverse |
| 2025-01-27 | 1-for-100reverse |
| 2004-07-15 | 1-for-2reverse |
No one on the platform has traded CDT yet.
| $791772 |
| — |
| LIXTLixte Biotechnology Holdings, Inc. | $7.42 | -7.71% | $92M | — |
| NIVFNewGenIvf Group Limited | $0.54 | +3.34% | $304736 | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
@Mister_GoodEr0or @wolfhunter12 yea the reason for the T12 is that 1 dollar is a minimum bid rule, all of these stocks like $CDT or such they may be under 1 dollar but if they get a letter they usually get 180 days to hit that target in the case of $ILLR it seems they gave them extra time on top of the regular 180. The problem is those who pumped this stock should have warned all those they where pushing that tofay was the last day and it had alread fallen short by 5 days.
View on StockTwits ↗$TNMG well 80 cents is a strong base, at least we know we found the bottom, the buying continues, should see past $1 here shortly, great start! $EZGO $NCT $CDT
View on StockTwits ↗$CDT so they hired a new auditor which means they are possibly getting this together.. I bought in small at .56
View on StockTwits ↗$CDT so July 10 or de-list? reading conflicting reports. Serious question.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.